Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 4Lymphoma, B-Cell 4Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Lymphoma, Non-Hodgkin 2Recurrence 1Leukemia, Prolymphocytic 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 240Rituximab 187fludarabine phosphate 129Etoposide 110Peripheral Blood Stem Cell Transplantation 108Mycophenolic Acid 94Filgrastim 91Melphalan 90Whole-Body Irradiation 88fludarabine 80Busulfan 80Tacrolimus 71Cytarabine 66Cyclosporine 66Radiotherapy 62Methotrexate 53Antilymphocyte Serum 53Granulocyte Colony-Stimulating Factor 51Vincristine 49Carmustine 48Doxorubicin 41Prednisone 37Thiotepa 33Bendamustine Hydrochloride 32Bortezomib 30Methylprednisolone 29Dexamethasone 28Stem Cell Transplantation 27thymoglobulin 26ibritumomab tiuxetan 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Non-Hodgkin × tafasitamab × Clear all
NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center

Phase 1 Not yet recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05583071 2025-08-13

MTR²

University of Cologne

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡